Hsbc Holdings PLC Has $150,000 Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Hsbc Holdings PLC increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 57.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 76,261 shares of the company’s stock after buying an additional 27,954 shares during the quarter. Hsbc Holdings PLC owned 0.11% of Amylyx Pharmaceuticals worth $150,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in AMLX. Vanguard Group Inc. grew its holdings in Amylyx Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company’s stock worth $15,189,000 after acquiring an additional 72,573 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Amylyx Pharmaceuticals by 5.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock worth $18,501,000 after purchasing an additional 69,733 shares during the last quarter. Acadian Asset Management LLC bought a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $2,300,000. Farallon Capital Management LLC bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter valued at about $3,267,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Amylyx Pharmaceuticals by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 970,555 shares of the company’s stock valued at $2,757,000 after buying an additional 75,775 shares during the last quarter. Institutional investors and hedge funds own 95.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AMLX shares. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. The Goldman Sachs Group boosted their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Friday, July 12th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.60.

Amylyx Pharmaceuticals Stock Up 6.1 %

NASDAQ:AMLX opened at $3.12 on Friday. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.58 and a twelve month high of $19.95. The company has a fifty day moving average of $2.42 and a 200-day moving average of $2.15. The firm has a market capitalization of $212.18 million, a P/E ratio of -2.92 and a beta of -0.55.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.35). The company had revenue of ($1.02) million during the quarter, compared to the consensus estimate of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same period last year, the firm posted $0.31 earnings per share. On average, analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 18,589 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total value of $59,484.80. Following the completion of the sale, the chief executive officer now owns 3,120,569 shares of the company’s stock, valued at approximately $9,985,820.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Justin B. Klee sold 18,589 shares of Amylyx Pharmaceuticals stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $59,484.80. Following the completion of the sale, the chief executive officer now owns 3,120,569 shares of the company’s stock, valued at approximately $9,985,820.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Camille L. Bedrosian sold 11,442 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $3.20, for a total transaction of $36,614.40. Following the sale, the insider now owns 143,801 shares of the company’s stock, valued at $460,163.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 11.70% of the stock is owned by company insiders.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.